KBY Biotech Indexv0.0.34
Search
← Pipeline|Tirasotorasib

Tirasotorasib

Phase 1
VKT-5480
By Viking Therapeutics
Source: Trial-derived·Trials: 1
Modality
Fusion Protein
MOA
IL-23i
Target
CFTR
Pathway
Innate Imm
MMWet AMDGBM
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
Jun 2020
Phase 1Current
NCT03792158
487 pts·GBM
2020-06→TBD·Completed
487 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1
Complet…
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03792158Phase 1GBMCompleted487NT-proBNP
Competitors (10)
DrugCompanyPhaseTargetMOA
NidasacituzumabEli LillyApprovedCFTRTYK2i
DatoglumideAbbVieApprovedCFTRCAR-T CD19
SNY-7254SanofiPhase 2CFTRHER2
SNY-5894SanofiApprovedCFTRSTINGag
GSK-6983GSKPhase 2ALKIL-23i
MotarapivirGSKPreclinicalAuroraAIL-23i
ZenotapinarofVertex PharmaPreclinicalCD38IL-23i
SovarelsinBioMarinPhase 2CFTRJAK1/2i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
BemasotorasibExelixisPhase 2CD38IL-23i